Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
olaparib
Research
PARP combo shows promise in ovarian and breast cancer models
Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.
Arlene Weintraub
Oct 24, 2020 4:00am
Could AstraZeneca’s ovarian cancer drug also treat glioblastoma?
Nov 6, 2017 8:39am
Moving PARP inhibitors beyond BRCA cancers
Jul 26, 2017 3:14pm
Medivation’s VP of clinical development jumps ship to rival PARP biotech
Aug 25, 2016 6:09am
UPDATED: Q2 clear-out sees AstraZeneca dump gastric cancer, NASH PhIII studies
Jul 28, 2016 4:17am
